TROIANI , Teresa

Last name: TROIANI

First name: Teresa

2011 (v1)

Publication

Metadata-only

MEK inhibitor as a single agent and in combination with everolimus or sorafenib in a panel of colorectal cancer cell lines: implication for multitargeted approach

MARTINELLI, Erika TROIANI, Teresa MORGILLO, Floriana

No description

Uploaded on: April 14, 2023
2011 (v1)

Publication

Metadata-only

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors

MORGILLO, Floriana D'AIUTO E TROIANI, Teresa

No description

Uploaded on: April 14, 2023
2013 (v1)

Publication

Metadata-only

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines

MORGILLO, Floriana SASSO, Ferdinando Carlo Della Corte CM

No description

Uploaded on: March 27, 2023
2015 (v1)

Publication

Metadata-only

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab

Napolitano S Martini G RINALDI, Barbara

Purpose: In colorectal cancer, the activation of the intracellular RAS–RAF and PIK3CA–AKT pathways has been implicated in the resistance to anti-EGFR mAbs. We have investigated the role of regorafenib, an oral multikinase inhibitor, in combination with cetuximab, an anti-EGFR mAb, to overcome anti-EGFR resistance. Experimental Design: We have...

Uploaded on: April 14, 2023
2017 (v1)

Publication

Metadata-only

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer

Belli, Valentina Sforza, Vincenzo Cardone, Claudia

Regorafenib, an oral multikinase inhibitor, has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients that have progressed after all standard therapies. However, novel strategies to improve tolerability and enhance anti-cancer efficacy are needed.

Uploaded on: April 14, 2023
2013 (v1)

Publication

Metadata-only

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

MARTINELLI, Erika TROIANI, Teresa D'Aiuto, Elena

The RAS/RAF/MEK/MAPK and the PTEN/PI3K/AKT/mTOR pathways are key regulators of proliferation and survival in human cancer cells. Selective inhibitors of different transducer molecules in these pathways have been developed as molecular targeted anti-cancer therapies. The in vitro and in vivo anti-tumor activity of pimasertib, a selective MEK 1/2...

Uploaded on: April 14, 2023

TROIANI , Teresa

Recent uploads